Hyperbilirubinemia and Associated Factors Among Neonates Admitted to the Neonatal Care Unit in Jimma **Medical Center**

Clinical Medicine Insights: Pediatrics Volume 17: 1-10 © The Author(s) 2023 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/11795565231193910



Sintayehu Asaye¹, Misgana Bekele¹, Aklilu Getachew¹, Diriba Fufa², Tesfaye Adugna³ and Edosa Tadese¹

¹School of Medical Laboratory Sciences, Jimma University, Jimma, Ethiopia. ²Faculty of Medical Sciences, Jimma University, Jimma, Ethiopia. ³Department of Biomedical Sciences, Jimma University, Jimma, Ethiopia.

ABSTRACT

BACKGROUND: Neonatal hyperbilirubinemia is a widespread and significant clinical problem among neonates worldwide. Globally, every year about 1.1 million babies develop it and the vast majority reside in South Asia and sub-Saharan Africa. Studies on the magnitude and factors associated with neonatal hyperbilirubinemia are limited in Ethiopia. So this study was aimed at assessing the prevalence and associated factors of neonatal hyperbilirubinemia among hospitalized neonates in the neonatal intensive care unit of Jimma Medical Center (JMC), Jimma, South West Ethiopia.

DESIGN: Hospital-based cross-sectional study was conducted at JMC from July 24 to October 19, 2020.

METHODS: A total of 222 neonates with their mothers were included and conveniently selected. Data was collected by interviewing mothers through structured questionnaires and reviewing neonates' medical records using a checklist. Multivariable binary logistic regression analyses were employed to identify factors associated with neonatal hyperbilirubinemia.

RESULTS: from a total of neo-maternal pairs included in the studies; the proportion of Neonatal hyperbilirubinemia was found to be 94 (42.3%). Neo-maternal ABO incompatibility 33 (35.1%), prematurity 41 (43.6%), sepsis 35 (37.2%), Neonatal birth asphyxia 20 (21.2%), and Rh isoimmunization 10 (10.6%) was significantly associated with neonatal hyperbilirubinemia.

CONCLUSION: The prevalence of neonatal hyperbilirubinemia in the study setting was high. Antenatal care (including both mother and fetus detail examination and follow-ups) as well as cautions during labor need to focus on since Neonatal hyperbilirubinemia-associated factors were maternal and neonatal. Hence, further assessment, early intervention, and timely treatment are important to mitigate the burdens in neonates due to hyperbilirubinemia.

KEYWORDS: Neonatal hyperbilirubinemia, Jimma Medical Centre

RECEIVED: October 27, 2022. ACCEPTED: July 25, 2023. TYPE: Original Research

CORRESPONDING AUTHOR: Sintayehu Asaye, School of Medical Laboratory Sciences, Jimma University, Jimma, P.O Box 378, Ethiopia. Email: sintayehus955@gmail.com

Introduction

Hyperbilirubinemia is a condition in which excess bilirubin is in the blood. Bilirubin is a non-polar endogenous by-product of heme catabolism with 85% from normal senescent erythrocyte broken down and 15% from ineffective erythropoiesis or turnover of non-hemoglobin hem proteins.¹ In newborns, hyperbilirubinemia becomes clinically apparent as jaundice when total serum bilirubin concentration gets $\geq 5 \text{ mg/dL}$ in contrast to adults at $\geq 2 \text{ mg/dL}$. Accumulation of bilirubin in the skin and mucous membrane causes yellow discoloration of the skin and sclera of the eye and causes cephalocaudally in advancements.2

Excessive bilirubin induces acute and chronic bilirubin encephalopathy. Acute bilirubin encephalopathy involves clinical presentation of lethargy, hypotonia, poor suck, high-pitched cry, fever, and irritability. Chronic bilirubin encephalopathy (kernicterus) is a severe irreversible and devastating clinical tetrad consisting of movement disorders, auditory dysfunction, oculomotor impairments, and dental enamel hypoplasia³ where different risk factors cause and potentiate the passage of bilirubin into the brain of neonates and hence increase the risk of neurotoxicity.4

Neonatal hyperbilirubinemia is a ubiquitous health problem that occurs in 60% of full-term and 80% of preterm neonates.⁵ It is still the most common cause of re-hospitalization of the newborn in the first week of life^{6,7} that imposes many negative effects on both neonates and their families.8,9

Moreover, neonatal hyperbilirubinemia is common and inflicts significant burdens of mortality and morbidly globally. However, the incidence and burdens were unacceptably high in low-income and middle-income countries (LMICs).¹⁰⁻¹² There is a multiplicity of risk factors associated with maternal, prenatal, and neonatal factors related to the occurrence of neonatal hyperbilirubinemia that can be modifiable and manageable.¹³⁻¹⁷ In Nigeria, neonatal sepsis, prematurity, and G-6PD deficiency are factors significantly associated with neonatal hyperbilirubinemia¹⁷ while in Rwanda, birth weight, gestational age, neonatal gender, method of delivery, blood group incompatibility, infections, cesarean section, and prematurity are significantly associated with neonatal hyperbilirubinemia.¹⁸



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Neonatal mortality is alarmingly high¹⁹ and hyperbilirubinemia was among the causes of neonatal admission and death in Ethiopia.²⁰⁻²² Identification of predisposing factors and initiation of appropriate management is paramount in the preventions of hyperbilirubinemia complications. However, there are very little data available on the prevalence of neonatal hyperbilirubinemia and associated factors in Ethiopia particularly in Jimma medical center, as to the knowledge of the principal investigators no study conducted yet on the topic regardless of the burdens of the problems. Therefore, the present study aimed at determining the magnitude of hyperbilirubinemia and associated factors among neonates admitted to neonatal ICU in the study area.

Materials and Methods

Study area, design, and period

A hospital-based cross-sectional study design was used, from July 24 to October 19, 2020, at the Neonatal ICU of Jimma Medical Center (JMC). The hospital (JMC) is located in Jimma city, 352km southwest of the capital Addis Ababa. Jimma Medical Center is one of the oldest public hospitals in the country, which is established in 1930 E.C by Italian invaders. It has 800 beds with teaching and referral services in the Southwestern part of the country, for approximately 15000 inpatients, 160000 outpatient attendants, 11000 emergency cases, and 4500 deliveries annually coming to the hospital from the catchment population. The neonatal ICU is one of the ICU services that the hospital is currently running. It has 20 neonatal beds and 14 Kangaroo mother care (KMC) beds. The unit also has 3 incubators, 22 radiant warmers, and 3 continuous positive airway pressure (CPAP), 4phototherapy and oxygen concentrator machines. Additionally, there is pulse oximetry, glucometer, and neonatal resuscitation equipment. Advanced procedures such as exchange transfusions and Lumber punctures are performed at the center. The unit is staffed with pediatricians, pediatric residents, and neonatal nurses and is located adjacent to the labor ward to receive high-risk newborns from this unit. Furthermore, the unit also receives neonates referred from other health facilities and homes.

Participant's selection and exclusion

All neonates aged less than 28 days admitted to Neonatal ICU during the study period and mothers age 18 years and above with informed consent were included in the study. Whereas mothers were unable to give informed consent and unwillingness to participate, neonates with anomalies/malformations and less than 35 gestational age were excluded from the study.

Sample size determination and sampling techniques

The sample size was calculated using the single proportion formula by the following assumption, Proportion of neonatal hyperbilirubinemia is 37. 3%, confidence interval (95%), and a 5% margin of sampling error were tolerated. This gives a total sample size of 359 neonates, but since the estimated study population was less than 10 000. Thus correction formula was used and finally, 222 samples of neonates admitted were included.

The convenient sampling technique was used and the study subjects were consecutively recruited until the required minimum sample size of the study was fulfilled.

Data quality assurance

All quality assurance components were applied in course of these studies. To increase the reliability of data, 2 data collectors were assigned by team leaders of neonatal nurses based on their previous experience in data collection and language skills. Besides training on the data collection procedures was given to the data collector. The instrument used for collections of sociodemographic data was adopted from previous studies of related topics and validated standards like Ethiopian demographic health survey checklists. The study participants were fully informed about the aims of the study, assured about information obtained from them was only for research purposes, and information obtained was anonymized and coded. For laboratory data collection standard operating procedures were strictly followed and implemented before specimen collection up to recording and interpreting of the laboratory results both by those who collect the specimen in the ward and who processing in the lab. Hemolysis-free specimen, protected from light exposure/photo oxidations/and extreme colds of icebox was collected by neonatal nurses. The collected sample was taken from the Neonatal ICU ward and processed in the laboratory. All specimens were collected before administrations of phototherapy for neonates with signs and symptoms of hyperbilirubinemia. Then label the sample and the questionnaire paper with the same identification number to avoid any mix-ups or errors. The expired date of the reagent was checked before the analysis of samples. A blood sample of study subjects used for bilirubin determination was run with both internal quality control materials and manufacture-provided standards/controls. Post analytical data quality check was done by different statistical software through the double entry of data to prevent errors from occurring and the interpretation of results was according to the aims of the studies. The completeness of data was checked and supervised by the principal investigator on daily basis during the entire data collection period.

Data processing and analysis

All the data were cleaned, coded, and entered into Epi data version 3.1 and transferred to SPSS version 23.0 for analysis. Descriptive statistics like frequency, proportions, and percentage were used to summarize the study variable.

Bivariate and multivariate logistic regression models were used to assess how well predictor independent variables explain or predict dependent variables and control possible confounders

Table 1. Socio-demographic characteristics of mothers of neonates at neonatal ICU.

VARIABLE	CATEGORY	FREQUENCY	PERCENTAGE
Mothers age	<20	46	20.7
	20-35	176	79.3
Residence	Rural	122	55
	Urban	100	45
Occupation	House wives	159	71.6
	Government employed	29	13.1
	Non-government employed	34	15.3
Educational status	Unable to write and read	26	11.7
	Primary school	73	32.7
	Secondary school	79	35.4
	Higher educations	44	19.7
Previous deliveries history	Abortions	7	3.2
	Still birth	19	8.6
	Neonatal death	9	4.1
	Premature birth	5	2.3
	No bad delivery history	182	81.98

and identify the determinant factors associated with the prevalence of neonatal hyperbilirubinemia. *P*-value < .05 was considered statistically significant.

Data collection techniques

An interview-administered structured questionnaire was used to collect socio-demographic and clinical data of mothers and medical records of study subjects were also reviewed by using standard checklists.

About 2 mL of venous blood was collected by experienced neonatal nurses. Then the blood samples were centrifuged for 5 minutes at 4000 revolutions per minute (rpm) to separate serum from other contents of whole blood. The extracted serum was kept in Nunc tube under -200°C deep freeze until laboratory analysis for bilirubin. Later, these frozen sera were analyzed for serum total bilirubin and direct bilirubin by HumaStar 100, a chemistry analyzer (HUMAN Diagnostics, Wiesbaden Germany) fully automated auto analyzer by the direct endpoint enzymatic method. ABO/RH blood grouping of the study subject was determined by direct slide methods from a whole blood specimen.

Results

Socio-demographic and other characteristics of study subjects

In this study, a total of 222 neonates with their mothers were included and made a 100% response rate.

The median age of the study mothers was 26.34 years and more than three-fourths of them were between 20 and 35 years. About 122 (55.0%) mothers were living in rural areas. Of the total interviewed mothers, 159 (71.6%) were housewives. Regarding educational status, 11.7% were unable to read and write, 32.7% primary education, 35.4% secondary education, and 19.7% for higher education were documented study participants. Their previous delivery history revealed that 40 (18.0%) mothers were either history of abortion, stillbirth, neonatal death, or have a history of premature birth "Table 1."

Neonate clinical characteristics

One hundred thirty-eight (62.2%) neonates were male in sex and 42.3% of neonates' age on admission lies within early neonatal age. Moreover, about 146 (65.8%) neonates were delivered in full-term with a birth weight of 2.5 kg and above were 166 (74.8%). In this study, an Apgar score of 101 (45.5%) for neonates at 1 and 5 minute were recorded. Regarding the feeding status, 175 (78.8%) neonates fed breast milk exclusively and 116 (52.3%) feeding breast started within 1 hour of delivery. In this study, the blood group of neonates was assessed and blood groups "O," "A" "B," and "AB" were 102, 63, 46, and 11 respectively. Two hundred twelve (95.5%) of study neonates were rhesus positive. Birth complications were recorded in 10.3% of study subjects. Regarding danger signs and symptoms of neonates, 187 (84.2%) were admitted with one or more danger signs to NICU. Among study neonates, 24 (10.8%) had

Table 2.	Neonatal	characteristics	among	neonates	admitted to	o neonatal ICI	U.

CHARACTERISTICS	CATEGORY	FREQUENCY	PERCENTAGE
Sex of neonates	Male	138	62.2
	Female	84	37.8
Gestational age (wk)	<37	76	34.2
	37-42	146	65.8
Age of neonates at admission (d)	<1 d	114	51.35
	1-7 d	94	42.34
	>7 d	14	6.30
Birth weight (kg)	<2.5	56	25.2
	≥2.5	166	74.8
Apgar score recorded	Yes	101	45.5
	No	121	54.5
Feeding mode	Exclusive breast milk	175	78.8
-	Formula feeding	22	10
	Mixed	25	11.2
Feeding initiation	Normal	116	52.3
	Prolonged	106	47.7
Defecation pattern	Prolonged	24	10.8
	Normal	198	89.2
Antibiotic medications	Yes	180	81.1
	No	42	18.9
Danger sign on admission	Yes	187	84.2
	No	35	15.8
Birth complications on neonates	Yes	23	10.4
	No	199	89.6
Blood groups	0	102	45.9
	А	63	28.4
	В	46	20.7
	AB	11	5
RH factor	Pos.	212	95.5
	Neg.	10	4.5

prolonged durations of defecations or meconium excretions. One hundred eighty (81.1%) admitted neonates administered one or combinations of antibiotic medication "Table 2."

Maternal clinical characteristics

Regarding antenatal care (ANC) follow-up, 216 (97.3%) respondents had at least one follow-up during their pregnancy.

Two hundred and thirteen (95.9%) neonates were delivered at health institutions. Home delivery was reported by 9 (4.1%) mothers. Concerning the mode of delivery, spontaneous vaginal delivery accounted for 146 (65.8%) whereas cesarean section 76 (34.2%) mothers. The normal duration of labor was recorded by 159 (71.6%) participants. Oxytocin was used as induction or augmentation of labor by 63 (16.6%) mothers. In this study, 33 (14.9%) delivery of mothers were in breech or Table 3. Maternal clinical characteristics of the admitted neonates to neonatal ICU.

No62.7Delivery placeHealth institution21395.9Home94.1Delivery typesNormal vaginal14665.8Cesarean section7634.2Duration of laborProlonged6328.4Duration of laborCephalic18985.1Fetal presentationsCephalic18985.1Teach3314.914.9Membrane rupturePROM2310.4Presence of MAS during deliverYes4218.9Presence of MAS during deliverYes4319.4IntersparturYes4319.4No17980.611.1IntersparturYes00Previous treatment for RH incompatibilityYes20.9Parity of mothersPrim parity8136.5Inter-pregnancy interval of mother-2y8539.7Vethers blood typeO13460.4Ag4620.739.7	CHARACTERISTICS	CATEGORY	FREQUENCY	PERCENTAGE
Delivery placeHealth institution21395,9Home94.1Delivery typesNormal vaginal14665.8Cesarean section7634.2Duration of laborProlonged6328.4Duration of laborCephalic15971.6Fetal presentationsCephalic18985.1Fetal presentationsCephalic18985.1Presence of MAS during deliverPROM2310.4Intrapartum19988.681.1Intrapartum18081.181.1Intrapartum18081.181.1InterserueYes4218.9Presence of MAS during deliverYes4391.4InterserueNo17980.6History of blood transfusionYes20.9Previous treatment for RH IncompatibilityYes20.9Parity of mothersPrim parity8136.5Inter-pregnancy interval of mother<2y	ANC follow up	Yes	216	97.3
Home94.1Delivery typesNormal vaginal14665.8Cesarean section7634.2Duration of laborProlonged6328.4Normal15971.6159Fetal presentationsCephalic18985.1TeresentationsPROM2310.4Intrapartum19989.618.9Presence of MAS during deliverYes4218.9Interpartum18081.111.1Interpartum17980.611.1InterpartumYes00No222100100Previous treatment for RH incompatibilityYes20.9No22099.0990.9Partup of mothersPrin parity8165.5Multiparity of mothers2y5639.7Vothers blood typeQ13460.4A4620.7860.4A4620.7860.4A4620.7860.4A4620.7860.4A4620.7860.4A4620.7860.4A4620.7860.4A4620.7860.4A4620.7860.4A4620.7860.4A4620.7860.4A4620.7860.4 <td></td> <td>No</td> <td>6</td> <td>2.7</td>		No	6	2.7
Delivery typesNormal vaginal14665.8Cesarean section7634.2Duration of laborProlonged6328.4Normal15971.6Fetal presentationsCephalic18985.1Membrane rupturePROM2310.4Intrapartum19989.6Presence of MAS during deliverYes4218.9Presence of MAS during deliverYes4319.4Interspartum19080.661.1Interspartum19080.661.1Prevence of MAS during deliverYes00No17980.661.1InterspartumYes00No22210065.5Previous treatment for PH incompatibilityYes20.9Previous treatment for PH incompatibilityYes14.1	Delivery place	Health institution	213	95.9
Cesarean section7634.2Duration of laborProlonged6328.4Normal15971.6Felal presentationsCephalic18985.1Tesenet attomsBreech3314.9Wembrane rupturePROM230.4Intrapartum19989.634Presence of MAS during deliverYes4218.9Presence of MAS during deliverYes3119.4Inters during pregnancyYes319.4Istory of blood transfusionYes20.0Previous treatment for RH incompatibilityYes20.9Parity of mothersQuity arity8136.5Inter-pregnancy interval of mother2.98560.3Parity of blood typeQ13460.4Atter pregnancy interval of motherQuity arity13460.4Atter pregnancy interval of motherQuity arity3460.4Atter pregnancy interval of motherQuity arity3460.4Atter pregnancy interval of motherQuity arity13460.4Atter pregnancy interval of motherAtter pregnancy60.460.4Atter pre		Home	9	4.1
Prolonged6328.4Normal15971.6Fetal presentationsCephalic18985.1Breech3314.9Membrane rupturePROM2310.4Intrapartum19989.6Presence of MAS during deliverYes4218.9Presence of MAS during deliverYes4319.4Intrapartum18081.119.4Inters during pregnancyYes4319.4Yeso0010Previous treatment for FH incompatibilityYes20.0Parity of mothersPrim parity8136.5Inter-pregnancy interval of mother2y8560.3Parity of blood typeQ13460.4Aga4620.716.2Aga662.7	Delivery types	Normal vaginal	146	65.8
Normal1597.6Fetal presentationsCephalic18985.1Breech3314.9Membrane rupturePROM2310.4Intrapartum19989.6Presence of MAS during deliverYes4218.9Presence of MAS during deliverYes4319.4Intess during pregnancyYes4319.4History of blood transfusionYes00Previous treatment for RH incompatibilityYes20.9Previous treatment for RH incompatibilityYes20.9Parity of mothersPrim parity8136.5Mutiparity14163.560.3Mutiparity14163.560.3Previous treatment of the mother<2y		Cesarean section	76	34.2
Fetal presentationsCephalic18985.1Breech3314.9Membrane rupturePROM2310.4Intrapartum19989.6Presence of MAS during deliverYes4218.9Presence of MAS during pregnancyYes4319.4Ilness during pregnancyYes4319.4History of blood transfusionYes00Previous treatment for RH incompatibilityYes20.9Previous treatment for RH incompatibilityYes20.9Parity of mothersPrim parity8136.5Inter-pregnancy interval of mother<2y	Duration of labor	Prolonged	63	28.4
Breech3314.9Membrane rupturePROM2310.4Intrapartum19969.6Presence of MAS during deliverYes4218.9Presence of MAS during pregnancyYes4319.4Illness during pregnancyYes4319.4Illness during pregnancyYes00tistory of blood transfusionYes00Previous treatment for RH incompatibilityYes20.9Previous treatment for RH incompatibilityYes20.9Previous treatment for RH incompatibilityYes20.9Previous treatment for RH incompatibilityYes20.9Parity of mothers22y8560.3Inter-pregnancy interval of mother22y5639.7Mothers blood typeO13460.4AB62.7662.7		Normal	159	71.6
Membrane rupturePROM2310.4Intrapartum19989.6Presence of MAS during deliverYes4218.9No18081.1Ilness during pregnancyYes4319.4History of blood transfusionYes00Previous treatment for RH incompatibilityYes2100Previous treatment for RH incompatibilityYes20.9Parity of mothersPrim parity8136.5Inter-pregnancy interval of mother<2y	Fetal presentations	Cephalic	189	85.1
Intrapartum19988.6Presence of MAS during deliverYes4218.9No18081.181.1Ilness during pregnancyYes4319.4Ilness during pregnancyYes00History of blood transfusionYes00Previous treatment for RH incompatibilityYes20.9Previous treatment for RH incompatibilityYes20.9Parity of mothersPrim parity8136.5Multiparity14163.560.3Previous treatment for DM mother<2y		Breech	33	14.9
Presence of MAS during deliver Yes 42 18.9 No 180 81.1 Illness during pregnancy Yes 43 19.4 No 179 80.6 History of blood transfusion Yes 0 0 No 222 100 100 Previous treatment for RH incompatibility Yes 2 0.9 Previous treatment for RH incompatibility Yes 2 0.9 Parity of mothers Prim parity 81 36.5 Inter-pregnancy interval of mother <2y	Membrane rupture	PROM	23	10.4
No 180 81.1 Ilness during pregnancy Yes 43 19.4 No 179 80.6 History of blood transfusion Yes 0 0 No 222 100 Previous treatment for RH incompatibility Yes 2 0.9 Previous treatment for RH incompatibility Yes 2 0.9 Parity of mothers Prim parity 81 36.5 Multiparity 141 63.5 60.3 Previous treatment for RH incompatibility 2y 85 60.3 Previous treatment for RH incompatibility 2y 85 60.3 Previous treatment for RH incompatibility 2y 85 60.3 Previous interval of mother 2y 85 60.3 Previous blood type O 134 60.4 A 46 20.7 B 36 16.2 AB 6 2.7		Intrapartum	199	89.6
Ilness during pregnancy Yes 43 19.4 No 179 80.6 History of blood transfusion Yes 0 0 No 222 100 Previous treatment for RH incompatibility Yes 2 0.9 Previous treatment for RH incompatibility Prim parity 81 36.5 Inter-pregnancy interval of mother $< 2y$ 85 60.3 $> 2y$ 56 39.7 36 Mothers blood type O 134 60.4 A 46 20.7 B 36 <td< td=""><td>Presence of MAS during deliver</td><td>Yes</td><td>42</td><td>18.9</td></td<>	Presence of MAS during deliver	Yes	42	18.9
No17980.6History of blood transfusionYes00No222100Previous treatment for RH incompatibilityYes20.9No22099.09Parity of mothersPrim parity8136.5Multiparity14163.5Inter-pregnancy interval of mother $< 2y$ 5639.7Vothers blood typeO13460.4A4620.7B3616.2AB62.73636.5		No	180	81.1
History of blood transfusionYes00No222100Previous treatment for RH incompatibilityYes20.9No22099.09Parity of mothersPrim parity8136.5Multiparity14163.5Inter-pregnancy interval of mother $< 2y$ 8560.3 $> 2y$ 5639.7Mothers blood typeO13460.4A4620.7B3616.2AB62.7	Illness during pregnancy	Yes	43	19.4
No222100Previous treatment for RH incompatibilityYes20.9No22099.09Parity of mothersPrim parity8136.5Multiparity14163.5nter-pregnancy interval of mother<2y		No	179	80.6
Previous treatment for RH incompatibilityYes20.9No22099.09Parity of mothersPrim parity8136.5Multiparity14163.5nter-pregnancy interval of mother<2y	History of blood transfusion	Yes	0	0
No22099.09Parity of mothersPrim parity8136.5Multiparity14163.5nter-pregnancy interval of mother $<2y$ 8560.3 $>2y$ 5639.7Mothers blood typeO13460.4A4620.7B3616.2AB62.7		No	222	100
Parity of mothersPrim parity 81 36.5 Multiparity141 63.5 nter-pregnancy interval of mother $<2y$ 85 60.3 $>2y$ 56 39.7 Mothers blood typeO 134 60.4 A 46 20.7 B 36 16.2 AB 6 2.7	Previous treatment for RH incompatibility	Yes	2	0.9
Multiparity14163.5nter-pregnancy interval of mother $<_{2y}$ 8560.3 $>_{2y}$ 5639.7Mothers blood typeO13460.4A4620.7B3616.2AB62.7		No	220	99.09
nter-pregnancy interval of mother $<_{2y}$ 85 60.3 \geq_{2y} 56 39.7 Mothers blood type O 134 60.4 A 46 20.7 B 36 16.2 AB 6 2.7	Parity of mothers	Prim parity	81	36.5
≥2y 56 39.7 Mothers blood type O 134 60.4 A 46 20.7 B 36 16.2 AB 6 2.7		Multiparity	141	63.5
Mothers blood type O 134 60.4 A 46 20.7 B 36 16.2 AB 6 2.7	Inter-pregnancy interval of mother	<2y	85	60.3
A 46 20.7 B 36 16.2 AB 6 2.7		≥2y	56	39.7
B 36 16.2 AB 6 2.7	Mothers blood type		134	60.4
AB 6 2.7		А	46	20.7
		В	36	16.2
		AB	6	2.7
H factor Pos. 210 94.6	RH factor	Pos.	210	94.6
Neg. 12 5.4		Neg.	12	5.4

non-cephalic presentations. Gestational diabetes mellitus by 6 (2.7%), hypertension by 20 (9.0%), the premature rupture of membrane (PROM) by 23 (10.4%), meconium aspirated syndrome (MAS) 42 (18.9%), and anemia by 7 (3.2%) mothers are identified as a complication during pregnancy. ABO blood group of mothers was assessed and recorded as "O," "A" "B," and "AB" by 134, 46, 36, and 6, 60.4%, 20.7%, 16.2%, 2.7% respectively. Similarly, 5.4% of study participant mothers were

rhesus negative. Previous treatment for RH immunizations was recorded only in 2 study participant mothers. None of the studies subject mothers have received blood and blood products during their pregnancy or previously. About parity and gravida of mothers, 81 (36.5%) and 141 (63.5%) were prim parity and multiparty respectively. Eighty-five (60.3%) of studies mothers had inter-pregnancy intervals of less than 2 years "Table 3." Variables were screened by binary logistic regression analysis: Sex of neonate, age of neonates, exclusive breastfeeding, induction of labor, neonatal birth asphyxia, sepsis, ABO blood incompatibility, Rh incompatibility, prolonged defecations of meconium, ampicillin treatment, leukocytosis, thrombocytopenia, prematurity hypoglycemia, and others in neonates had a significant association with neonatal hyperbilirubinemia at *P*-value $\leq .25$ "Table 4."

Multivariable binary logistic regression analysis was done by taking variables showing significant association on bivariate analysis at a *P*-value of \leq .25 to control (adjust) the possible confounding. Sex of neonate, age of neonates, exclusive breastfeeding, induction of labor, neonatal birth asphyxia, sepsis, ABO blood incompatibility, RH incompatibility, and prolonged defecations of meconium, Leukocytosis, Thrombocytopenia, and Prematurity had a significant association with neonatal hyperbilirubinemia at *P*-value < .05 of multivariate analysis "Table 5."

Discussion

Neonatal hyperbilirubinemia incorporates vital importance on baby morbidity and hospitalizations worldwide wherever the overwhelming majority of the affected neonates reside in sub-Saharan Africa and South Asia.¹¹ During this study prevalence of neonatal hyperbilirubinemia was 94 (42.3%) which was a lower finding than reported in Malaysia (63%)²³ and South Africa (55.2%).²⁴ However, it absolutely was beyond a finding from Pakistan (27.6%),¹⁰ Benin (26.5%),¹⁷ and Ghana (32.9%).24 It was also quite higher as compared to finding from Nepal,¹⁷ Indonesia (4.08%),²⁵ Iran (12.6%),²⁶ Congo Brazzaville (7.2%),²⁷ and Uganda (22.7%).²⁸ Southeast Nigeria (35%),²⁹ Rwanda (44.3%),¹⁸ and Black lion Ethiopia.³⁰ This disparity could be due to sampling size, study period difference, study design, study area, methodology difference, coverage of obstetrics care, definitions of hyperbilirubinemia, and characteristics of the study participant. This study revealed that male neonates had higher odds of developing neonatal jaundice [AOR = 2.234; 95% CI (1.058-4.716)] compared to their female counterparts. The finding was corroborated by studies done in Nepal,³¹ and Nigeria.³² Conversely, this result was concordant with findings in Croatia,25 and Iran.26 Furthermore, this could be due to that male newborns have comparatively low levels of ligand which may not be able to process all the bilirubin formed from red blood cells and due to hormonal effects of transporter protein where testosterone down regulates membrane transporter protein which is involved in bilirubin metabolism.

The most affected age group by neonatal hyperbilirubinemia in this study was those neonates in early neonatal periods (1-7 days) at admission which was 50% and those >7 days old were 6.4%. Other studies in black lion hospitals showed that 52.5% of hyperbilirubinemia neonates were 3 to 6 days old at admission and those >6 days old were 32.5%.¹¹ This showed that as the age of the neonate increases the prevalence of neonatal hyperbilirubinemia decreases; the prevalence of neonatal hyperbilirubinemia is inversely proportional to the age of the neonate.

ABO incompatibility and hyperbilirubinemia were significantly associated in our study (AOR 3.942, CI 1.688-9.206). The number of ABO incompatibility in our study was 54% and 61.2% of them represent 35.10% of the total hyperbilirubinemia infants who developed HB in our study. This finding was consistent with other studies conducted in Northern India,¹⁴ Nepal,¹⁵ and Ethiopia.²² This finding suggests the possibility of ABO-associated hemolysis as one of the causes of NHB in our study population.

Rh isoimmunization is the most significant cause of hemolytic hyperbilirubinemia in newborn babies. In our study, 12 mother-infant pairs had Rh discordance; 10 participants developed significant hyperbilirubinemia whereas the odds of developing hyperbilirubinemia were significantly high (AOR = 7.296, CI 1.138-46.758). Intravenous immunoglobulin is being used for the treatment of jaundice in newborn infants with hemolytic anemia. This finding was higher than the works of Eleje et al in Nigeria (21.3% of Rh discordant develops Neonatal hyperbilirubinemia) compared to 83.3% in our finding.³³ This disparity can be explained by the administration of anti-D immunoglobulin (33 (46.5%) of these received anti-D prophylaxes) compared to 2 (16.66%) in our findings that demonstrated the relevance of antenatal screening and prevention measures.

In addition, the study discovered that neonatal hyperbilirubinemia had a significant association with sepsis. The odds of neonatal hyperbilirubinemia among neonates who had sepsis were 2.9 times higher compared with those neonates who had no sepsis diagnosis [AOR=2.944; 95% CI (1.164-7.447)]. Sepsis was also identified as the possible cause of neonatal jaundice in studies conducted in India,14,31 Ghana,34 and Ethiopia.²² This similarity in finding might be due to similarities in the study setting that is, intensive care unit (sepsis was a common finding in any hospital admissions and need intensive care). Sepsis could be due to poor hygienic environment, poor obstetric and nursery care, and sepsis would also possibly cause hemolysis of red blood cells and hepatic dysfunction that leads to cholestasis from septic states that leads to accumulation of serum bilirubin within the body, and conjointly arise from varied drugs used for sepsis treatment.

Birth asphyxia was also an important determinant of Neonatal hyperbilirubinemia [AOR = 4.131; 95% CI (1.367-12.481)]. Different studies conducted in Southern Nigeria,³³ and Northern Ethiopia³⁵ supported that neonatal jaundice is influenced by birth asphyxia. This similarity in finding was because perinatal asphyxia remains a common problem in the neonatal nursery and is a significant coincidence with neonatal hyperbilirubinemia in neonatal intensive care and it was also

VARIABLES	CATEGORY	HYPERBI	LIRUBINEMIA	P-VALUE	COR	95% CI	
		YES	NO	_		LOWER	UPPER
Sex of neonates	Male	72	66	.000**	3.074	1.704	5.546
	Female	22	62		1		
Age of neonates	<1 d	41	73	.615	0.749	0.243	2.308
	1-7 d	47	47	.619	1.333	0.429	4.140
	>7 d	6	8	.127*			
Exclusive breast feeding	Yes	85	90	.001**	3.988	1.819	8.740
	No	9	38		1		
Meconium excretions	Prolonged	18	6	.001**	4.816	1.830	12.67
	Normal	76	122		1		
Ampicillin treatment	Yes	17	14	.132*	1.798	0.837	3.860
	No	77	114		1		
Labor types	Induced	39	24	.000**	3.073	1.679	5.624
	Spontaneous	55	104		1		
Neonatal sepsis	Yes	35	35	.118*	1.576	0.891	2.790
	No	59	93				
Neonatal birth asphyxia	Yes	20	18	.150*	1.674	0.830	3.379
	No	73	110		1		
Hypoglycemia and others in neonates	Yes	31	31	.152	1.540	0.853	2.778
in noonates	No	63	97				
ABO incompatibility	Yes	33	21	.002**	2.756	1.467	5.181
	No	61	107		1		
RH incompatibility	Yes	10	2	.010**	7.500	1.603	35.092
	No	84	126		1		
Leukocytosis in neonates	Yes	23	15	.014**	2.440	1.194	4.989
	No	71	113				
Thrombocytopenia	Yes	30	20	.005**	2.531	1.328	4.823
	No	64	108				
Gestational age	Preterm	41	35	.012**	2.056	1.170	3.610
	Term	53	93		1		

Table 4. Bivariate logistic regression analysis of different factors with neonatal hyperbilirubinemia among neonates admitted to neonatal ICU.

Abbreviations: 1, reference; COR, crude odds ratio; CI, confidence interval. *P-value < .25. **P-value < .05.

an insult to the newborn due to lack of oxygen, lack of perfusion to various organs which ends up in multi-organ system dysfunction due to hypoxic damage principally on brain, lung, liver and intraventricular hemorrhage that affect bilirubin conjugation ability of the liver that leads to jaundice.³⁵ Also, perinatal asphyxia with the hypoxic-ischemic neurological disorder will disrupt the blood-brain barrier, thereby permitting free entry of the unconjugated bilirubin to the neurons leading to a neurological disorder. Besides, kidney damage perinatal asphyxia also causes less excretion of the conjugated bilirubin, thereby inflicting conjugated hyperbilirubinemia and jaundice.

VARIABLES	CATEGORY	HYPERBI	LIRUBINEMIA	<i>P</i> -VALUE	AOR	95% CI	
		YES	NO			LOWER	UPPER
Sex of neonates	Male	72	66	.035	2.234	1.058	4.716
	Female	22	62		1		
Age of neonates	<1 d	41	73	.387	1.996	0.417	9.554
	1-7 d	47	47	.009	8.171	1.678	39.794
	>7 d	6	8				
Exclusive breast feeding	Yes	85	90	.007	3.794	1.441	9.990
	No	9	38		1		
Meconium excretions	Prolonged	18	6	.003	6.800	1.908	24.237
	Normal	76	122		1		
Labor types	Induced	39	24	.002	3.734	1.653	8.433
	Spontaneous	55	104		1		
Neonatal sepsis	Yes	35	35	.023	2.944	1.164	7.447
	No	59	93				
Neonatal birth asphyxia	Yes	20	18	.012	4.131	1.367	12.481
	No	74	110		1		
ABO incompatibility	Yes	33	21	.002	3.942	1.688	9.206
	No	61	107		1		
RH incompatibility	Yes	10	2	.036	7.296	1.138	46.758
	No	84	126		1		
Leukocytosis in neonates	Yes	23	15	.0001	7.070	2.538	19.694
	No	71	113				
Thrombocytopenia in neonates	Yes	30	20	.011	2.924	1.279	6.681
ΠΕΟΠΑΙΕδ	No	64	108				
Gestational age	Preterm	41	35	.006	3.504	1.436	8.549
	Term	53	93		1		

Table 5. Multivariate logistic regression analysis of different factors with neonatal hyperbilirubinemia among neonates admitted to neonatal ICU.
--

Abbreviations: 1, reference; OR, adjusted odds ratio; CI, confidence interval. *P-value <.25. **P-value <.05.

In this study induction of labor with oxytocin had a significant effect on the development of hyperbilirubinemia in neonates [AOR = 3.734; 95% CI (1.653-8.433)]. Our study was consistent with the studies of Peter et al,¹⁶ Islam et al,³⁵ and Garosi et al.³⁶ However, the finding was discordant with the study of Kavehmanesh et al²⁶ and studies conducted in Poland.³⁷ Since Oxytocin causes osmotic swelling of erythrocytes leading to decreased deformability and hence more rapid destruction with resultant hyperbilirubinemia in the neonate. Neonatal hyperbilirubinemia had a significant association with the feeding mode of neonates particularly with exclusive breastfeeding [AOR = 3.794; 95% CI (1.441-9.990)]. The association was described in studies conducted by Seyedi et al³⁸ and Eleje³² This is due to decreased caloric intake/starvation, inhibition of hepatic excretion of bilirubin and an increase in intestinal absorption of bilirubin (enterohepatic circulation)³⁹ and a component of breast milk⁴⁰ are suggested mechanisms for the hyperbilirubinemia associated with breast-feeding.

Inadequate enteral feeding favors increased entero-hepatic circulation and delays defecations of meconium and in our study participants 47.8% of had prolonged initiation of breastfeeding after birth. Consequently, participants who had prolonged initiation of breastfeeding after birth were more likely to develop HB and have delayed patterns of defecations.³¹ Similarly, the odds of developing neonatal hyperbilirubinemia among neonates who had prolonged type defecations of meconium were 6.8 times higher compared with normal one [AOR=6.800; 95% CI (1.908-24.237)]. It was similar to the finding of Seyedi et al.³⁸ However, it was inconsistent with the study conducted in Turkey⁴¹ and Brazil.⁴² The disparity could be due to characteristics' of studies subjects that is, 34% of our study neonates were preterm in gestation and prematurity is associated with prolonged Passage of meconium when compared to term infants.⁴³ This is because 1g of wet meconium contains an equal amount of milligram of bilirubin, delayed passage of meconium, and decreased frequency of meconium passage may increase enterohepatic circulation and contribute to the development of jaundice in neonates.

Thirty- four percent of our study neonates were preterm in gestation which was consistent with available studies.³³ Neonates born preterm had higher chances of developing hyperbilirubinemia than neonates born at term [AOR=3.504; 95% CI (1.436-8.549)]. Prematurity was also identified as the possible cause of neonatal hyperbilirubinemia in studies conducted in India,⁴⁴ Iran,⁴³ and Ethiopia.¹¹ This more common in preterm infants was due to the relative immaturity of the red blood cells, hepatic cells, and gastrointestinal tract than in neonates born at term.

Hematological abnormality is one of the commonest problems encountered in the neonatal intensive care unit (NICU). Of this thrombocytopenia and leukocytosis is prevalent, associated with, and commonly follow hyperbilirubinemia due to bacterial infections.⁴⁵ Neonatal hyperbilirubinemia had significant association with both thrombocytopenia [AOR=2.924; 95% CI (1.279-6.681)] and leukocytosis [AOR = 7.070; 95% CI (2.538-19.694)] in our studies respectively. Most of the available works of literature associate thrombocytopenia with complications of phototherapy in hyperbilirubinemia neonates⁴⁶; however thrombocytopenia due to hereditary thrombotic thrombocytopenic purpura (TTP) caused by ADAMTS13 mutations is a rare but serious condition, often presenting during the newborn period with microangiopathic hemolytic anemia could be a risk factor for neonatal hyperbilirubinemia.47

Study limitation

The study design has some limitations in particular the generalizability of findings will be limited to infants admitted to the NICU. Since the present study evaluated only hospitalized newborns and the status of outpatient infants is not known. The studies also could not do blood film and G6PD assay to comment on and confirm infection and hemolysis.

Conclusions and Recommendation

Our study indicated the high prevalence of hyperbilirubinemia among neonates admitted to NICU. Gender, Neo-maternal ABO incompatibility, Sepsis, Neonatal birth asphyxia prematurity, and induction of labor with oxytocin were the risk factors associated with the prevalence of hyperbilirubinemia in neonates. Therefore, it is mandatory to screen, treat, and manage hyperbilirubinemia and its associated risk factors in neonates admitted to NICU.

Abbrevations

APGAR: Appearance, Pulse, Grimace, Activity, Respiration
G6PD: Glucose 6 phosphate dehydrogenase
JMC: Jimma medical center.
NICU: Neonatal intensive care unit.
TSB: Total serum bilirubin

Declarations

Ethics approval and consent to participate

This study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving research study participants were approved by the ethical review board at Jimma University.

Ethical clearance was obtained from the ethical review board of the Institute of Health Sciences, Jimma University with a reference number of IRB 000132/2020 to conduct the study, to the JMC medical director. Next, a permission letter was obtained from the medical director of the Hospital to the department of pediatrics and neonatal head office to conduct the study. Before actual data collection, the purpose of the study was explained to each study participant. The data collected from each study participant were used only for this study. Written informed consent for the neonates was obtained from each study participant's mother. For illiterate or minor participants, informed consent was obtained from a legally authorized representative or legal guardian. For the study participants who cannot read and write, the informed consent was obtained after the data collectors have read the consent orally in the presence of a witness; sufficient time was given for comprehension or any question might be asked. Moreover, the study participants had been assured they had full right to withdraw from the study at any time.

Consent for publication Not applicable.

Author contributions

Sintayehu Asaye: Conceptualization; Formal analysis; Investigation; Project administration; Visualization; Writing – review & editing. Misgana Bekele: Data curation; Formal analysis; Funding acquisition; Writing – original draft. Aklilu Getachew: Supervision; Writing – review & editing. Diriba Fufa: Methodology; Writing – review & editing. Tesfaye Adugna: Project administration; Software. Edosa Tadese: Data curation; Supervision.

Acknowledgements

We would also like to thank data collectors, study participants, and supervisors as well as those who directly or indirectly contributed to this study.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Jimma University sponsored this study. However, it has no role in the decision to publish, manuscript preparation, and publication.

Competing interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Availability of data and materials

Data will be available upon the convincing request from the corresponding author.

ORCID iD

Sintayehu Asaye (D) https://orcid.org/0000-0003-1720-8011

REFERENCES

- Burtis C, Bruns D. Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics. 7th ed. Elsevir, Amesterdam, 2015.
- 2. Verma Y. Neonatal jaundice. Yuva J Med Sci. 2015;1:36-45.
- Das S, van Landeghem FKH. Clinicopathological spectrum of bilirubin encephalopathy/kernicterus. *Diagnostics*. 2019;9:24.
- Bhutani VK, Wong RJ. Bilirubin neurotoxicity in preterm infants: risk and prevention. J Clin Neonatol. 2013;2:61-69.
- Rohit M, Bhavesh M, PatelJaiminkumar P, Punitha K. Study of the morbidity and the mortality pattern in the neonatal intensive care unit at a Tertiary Care Teaching Hospital in Gandhinagar District, Gujarat, India. J Res Med Dent Sci. 2015;3:208-212.
- Lain SJ, Roberts CL, Bowen JR, Nassar N. Early discharge of infants and risk of readmission for jaundice. *Pediatrics*. 2015;135:314-321.
- Ys K, Gh Y, Jan F A. Morbidity and mortality among neonates admitted to a neonatal intensive care unit of a Tertiary Care Teaching Hospital of Jammu and Kashmir India. *Neonat Pediatr Med.* 2017;03:136.
- Yu TC, Nguyen C, Ruiz N, et al. Prevalence and burden of illness of treated hemolytic neonatal hyperbilirubinemia in a privately insured population in the United States. *BMC Pediatr.* 2019;19:53.
- Ekwochi U, Osuorah DC, Ndu IK, et al. The out-of-pocket cost of managing sick newborns in Enugu, southeast Nigeria. *Clinicoecon Outcomes Res.* 2014;6:29-35.
- Olusanya BO, Teeple S, Kassebaum NJ. The contribution of neonatal jaundice to global child mortality: findings from the GBD 2016 study. *Pediatrics*. 2018;141:e20171471.
- Slusher TM, Zamora TG, Appiah D, et al. Burden of severe neonatal jaundice: a systematic review and meta-analysis. *BMJ Paediatr Open*. 2017:25;1(1); 1:e000105.
- Greco C, Arnolda G, Boo NY, et al. Neonatal jaundice in low- and middleincome countries: lessons and future directions from the 2015 Don Ostrow Trieste Yellow Retreat. *Neonatol.* 2016;110:172-180.
- Agrawal V, Goyal AK, Sharma JN, Yadav MD. Different causes of prolonged unconjugated jaundice in the newborns. *Int J Contemp Pediatr.* 2017;4:984-988.
- Maamouri G, Khatami F, Mohammadzadeh A. Hyperbilirubinemia and neonatal infection. *Int J Pediatr.* 2013;1.
- Devi DS, Vijaykumar B. Risk factors for neonatal hyperbilirubinemia: a case control study. Int J Reprod Contracept Obstet Gynecol. 2017;6:198-202.
- Peters LL, Thornton C, de Jonge A, et al. The effect of medical and operative birth interventions on child health outcomes in the first 28 days and up to 5 years of age: a linked data population-based cohort study. *Birth.* 2018;45:347-357.
- Israel-Aina YT, Omoigberale AI. Risk factors for neonatal jaundice in babies presenting at the University of Benin Teaching Hospital, Benin City. Niger J Paediatr. 2012;39:159-163.

- Murekatete C, Muteteli C, Nsengiyumva R, Chironda G. Neonatal jaundice risk factors at a district hospital in Rwanda. *Rwanda J Med Health Sci.* 2020;3:204-213.
- Ethiopian Public Health Institute (EPHI) [Ethiopia] and ICF. Ethiopia Mini Demographic and Health Survey 2019: Key Indicators. EPHI and ICF; 2019.
- Mehretie K. Institution based prospective cross-sectional study on patterns of neonatal morbidity at Gondar University Hospital Neonatal Unit. *Ethiop J Health Sci.* 2016;26:73-79.
- Tewabe T, Mehariw Y, Negatie E, Yibeltal B. Neonatal mortality in the case of Felege Hiwot referral hospital, Bahir Dar, Amhara Regional State, North West Ethiopia 2016: a one year retrospective chart review. *Ital J Pediatr.* 2018;44:57-65.
- Kassa RT, Gudeta H, Assen ZM, Mulugeta Demlew T, Teshome GS. Neonatal hyperbilirubinemia: magnitude and associated etiologic factors among neonates admitted at Tikur Anbessa Specialized Hospital, Ethiopia. J Pregnancy Child Health. 2018;05:4.
- Awang H, Siti Mariam J, Wan Ishak NA, Dollah Z. Determinants of neonatal jaundice among newborns in Pasir Puteh District, Kelantan. Int J Public Health Clin Sci. 2019;6:2289-7577.
- Brits H, Adendorff J, Huisamen D, et al. The prevalence of neonatal jaundice and risk factors in healthy term neonates at National District Hospital in Bloemfontein. *Afr J Prim Health Care Fam Med.* 2018;10:a1582.
- Yahya N, Yuniati T, Lubis L. Characteristics of neonatal hyperbilirubinemia at West Java's Top Referral Hospital, Indonesia. *AMJ*. 2017;4:167-172.
- Kavehmanesh Z, Mohammadieh NE, Karimi Zarchi AA, Amirsalari S, KMZ, Torkaman M. Prevalence of readmission for hyperbilirubinemia in healthy newborns. *Iran J Pediatr.* 2008;18:130-136.
- 27. Bowassa GE, Ngono GTW, Ngakengni NY, et al. Jaundice in the newborn at the Teaching Hospital of Brazzaville. *Open J Pediatr.* 2019;09:111-118.
- Nyangabyaki-Twesigye C, Mworozi E, Namisi C, et al. Prevalence, factors associated and treatment outcome of hyperbilirubinaemia in neonates admitted to St Francis Hospital, Nsambya, Uganda: a descriptive study. *Afr Health Sci.* 2020;20:397-405.
- Onyearugha CN, Onyire BN, Ugboma HAA. Neonatal jaundice: prevalence and associated factors as seen in Federal Medical Centre Abakaliki. *Southeast Niger J Clin Med Res.* 2011;3:40-45.
- Mugadza G, Zvinavashe M, Gumbo Z, Stray-Pedersen B. Early breastfeeding initiation and incidence of severe neonatal jaundice in Chipinge district Zimbabwe. *Int J Contemp Pediatr.* 2017;4:1922-1926.
- Garg S, Mehta S, Sankhe A, Alukuchi S. Study of incidence of breastfeeding failure jaundice in cases of neonatal hyperbilirubinemia in a suburban hospital. *Int J Contemp Pediatr.* 2018;5:2188-2192.
- Eleje GU, Ilika CP, Ezeama CO. Feto-maternal outcomes of women with Rhesus iso-immunization in a Nigerian tertiary health care institution. J Preg Neonatal Med. 2017;1:21-27.
- Omekwe DE, Duke George M, Kennis BT, et al. Survey and management outcome of neonatal jaundice from a Developing Tertiary Health Centre, Southern Nigeria. *IOSR-JDMS*. 2014;13:35-39.
- Maisels MJ, Clune S, Coleman K, et al. The natural history of jaundice in predominantly breastfed infants. *Pediatrics*. 2014;134:e340-e345.
- Islam MT, Hoque SA, Nazir F, Bhuiyan MMR, Islam MN. Status of serum bilirubin, serum proteins and prothrombin time in babies with perinatal asphyxia. J Dhaka Natl Med Coll Hosp. 2013;18:43-46.
- Garosi E, Mohammadi F, Ranjkesh F. The relationship between neonatal jaundice and maternal and neonatal factors. *Iran J Neonatol.* 2016;7:37-40.
- Baranowska B, Kajdy A, Kiersnowska I, et al. Oxytocin administration for induction and augmentation of labour in Polish maternity units – an observational study. *Res Sq.* 2021;21:764.
- Seyedi R, Mirghafourvand M, Jannat Dost A, Mohammad-Alizadeh-Charandabi S, Asghari Jafarabadi M. Relationship between neonatal skin bilirubin level and severe jaundice with maternal, childbirth, and neonatal characteristics. *Iran J Neonatol.* 2019;10(2):61-67.
- Gourley GR. Breast-feeding, neonatal jaundice, and kernicterus. Semin Neonatol. 2002;7:135-141.
- Prameela KK; FRCP (Edin), FRCPCH (UK). Breastfeeding during breast milk jaundice - a pathophysiological perspective. *Med J Malaysia*. 2019;74:527-533.
- Nader S, Nader P, Dolvitsch D, Chinazzo HR. Association between delayed passage of meconium and neonatal jaundice in an University Hospital in Brazil. *Arch Dis Child*. 2012;97:A378-A539.
- 42. Abbas H, Hassan SU, Arif K, Zameer S, Ahmed N, Haq AA. Neonatal hyperbilirubinemia: a retrospective study. *J Saidu Med Coll Swat.* 2020;10:52-55.
- Alizadeh Taheri P, Sadeghi M, Sajjadian N. Severe neonatal hyperbilirubinemia leading to exchange transfusion. *Med J Islam Repub Iran*. 2014;28:64.
- Mesić I, Milas V, Medimurec M, Rimar Z. Unconjugated pathological jaundice in newborns. *Coll Antropol.* 2014;38:173-178.
- Nandyal SS, Shashikala P, Sahgal V. Study of thrombocytopenia in neonatal intensive care unit. *Indian J Pathol Oncol.* 2016;3:55-59.
- 46. Khera S, Gupta R. Incidence of thrombocytopenia following phototherapy in hyperbilirubinemia neonates. *MJAFI*. 2011;67:329-332.
- 47. Hager HB, Andersen MT. A neonate presenting with jaundice, anemia, and thrombocytopenia. *Blood.* 2018;131:1627.